Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

ABSTRACT:

Background

Despite repeated outbreaks, in particular the devastating 2014-2016 epidemic, there is no effective treatment validated for patients with Ebola virus disease (EVD). Among the drug candidates is the broad-spectrum polymerase inhibitor favipiravir, which showed a good tolerance profile in patients with EVD (JIKI trial) but did not demonstrate a strong antiviral efficacy. In order to gain new insights into the antiviral efficacy of favipiravir and improve preparedness and public health management of future outbreaks, we assess the efficacy achieved by ascending doses of favipiravir in Ebola-virus-infected nonhuman primates (NHPs).

Methods and findings

A total of 26 animals (Macaca fascicularis) were challenged intramuscularly at day 0 with 1,000 focus-forming units o

SUBMITTER: Guedj J 

PROVIDER: S-EPMC5870946 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature